Biotech Firm Bonshun Pharma's Hong Kong IPO Prospectus Expires After Six Months

CITIC0.77%
According to Zhitong Caijing, Bonshun Pharma's Hong Kong IPO prospectus, filed on January 22, 2026, expired today (July 22). CITIC CLSA International is the sole sponsor. The biotech company focuses on oncology and autoimmune disease treatments.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments